多替阿巴拉米片有什么作用

The ingredients are dolutegravir 50mg + abacavir 0.6g + lamivudine 0.3g. Three drugs are used for the treatment of HIV-1 infection. It is the only three-in-one compound drug containing dolutegravir. Dolutegra abalamib tablets have been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment for newly diagnosed AIDS patients.

From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in dolutea palamid tablets is significantly less than that of the other two drugs, making it less likely to develop drug resistance.

Dolutegra abalamib tablets integrate therapeutic drugs for different stages of viral infection into the same tablet. Patients only need to take one drug to achieve the effect of combined medication. One tablet is a complete treatment plan. One tablet a day can achieve the effect of cocktail therapy without food restrictions. It is important to note that although viral suppression with antiretroviral therapy has been shown to significantly reduce the risk of sexual transmission, residual risks cannot be ruled out. Precautions should be taken to prevent transmission in accordance with national guidance.

Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the life spans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day, one tablet at a time, on the Chinese market. The approval of the drug fills this gap and meets the urgent need for convenient medication use by doctors and patients."

Recommended related hot articles: /newsDetail/85408.html